Drug
Mgd013
Mgd013: highest development phase Phase 1, developed by Zai Lab. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Zai Lab
Trials
| Drug | Phase | Indication |
|---|---|---|
| MGD013 NCT04653038 | Phase 1 | Unresectable, Recurrent or Metastatic Melanoma |
Latest
No recent events.
Follow Mgd013 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.